- Sebetralstat Phase 3 KONFIDENT Clinical Trial Achieves Targeted Number of Attacks to Complete Trial - - Data Readout on Track for Early 2024; NDA Filing Expected H1 2024 - CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Dec. 7, 2023-- KalVista Pharmaceuticals, Inc ....

CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Dec. 5, 2023-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the compensation committee of KalVista’s board of directors granted four newly-hired employees inducement options to purchase an aggregate of 43,000 shares of...

– Patient perspectives on challenges with currently available parenteral on-demand HAE treatments explain basis for non-compliance with treatment guidelines – – Global prevalence of normal C1-inhibitor HAE (HAE-nC1-INH) may be greater than previously realized – CAMBRIDGE, Mass....

- Study completion activities underway; topline data expected early 2024 – - Largest-ever HAE clinical trial meets on-treatment attack target – - NDA submission remains on track for first half 2024 – CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Nov....

CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Nov. 7, 2023-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced it will...

CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Nov. 3, 2023-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the compensation committee of KalVista’s board of directors granted eight newly-hired employees inducement options to purchase an aggregate of 77,000 shares of...

CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Nov. 2, 2023-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced the acceptance of...

CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Oct. 24, 2023-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced the presentation...

CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Oct. 3, 2023-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the compensation committee of KalVista’s board of directors granted five newly-hired employees inducement options to purchase an aggregate of 103,000 shares of...

CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Sep. 19, 2023-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced it will present...